A practical reference on IGF-1 marker: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-17 and is reviewed periodically as new material appears.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
== Decay == Uranium-235 is an alpha emitter, producing thorium-231. Uranium-235 is the main progenitor of the actinium series, one of the principal actinide decay chains, as it is the longest-lived and sole primordial nuclide (aside from the final end product, lead-207). Beginning with naturally occurring uranium-235, this series includes isotopes of astatine, bismuth, francium, lead, polonium, protactinium, radium, radon, thallium, and thorium, all of which are present in natural uranium sources. The decay proceeds as (only main decay branches shown):
== Research == Several forms of lipodystrophy cause insulin resistance, which has responded favorably to thiazolidinediones. There are some indications that thiazolidinediones provide some degree of protection against the initial stages of breast carcinoma development. Evidence was emerging in 2008 that vitamin E with thiazolidinediones is effective in the treatment of non-alcoholic steatohepatitis due to their combined antioxidant and insulin sensitizing effects, producing histological improvements in steatosis severity. Thiazolindinediones induce adipogenesis in subcutaneous fat deposits by activating PPARγ receptors. This effect has been used in transgender patients to shift body fat distribution towards a more gynoid pattern.
=== Venom-induced pathology === As a consequence of the numerous activities the enzyme participates in, it could be deduced that there is likely some enzymatic function regarding the complex network of venom toxin activities. Recent findings suggest a more defined role for LAAO in venom-induced tissue damage. One study demonstrated that LAAO from Bothrops atrox venom causes cell death in human keratinocytes via a sequence of autophagy, apoptosis, and necrosis, driven primarily by hydrogen peroxide production. In vivo, co-injection of the antioxidant N-acetyl cysteine (NAC) significantly reduced dermonecrosis in mice, implicating LAAO-generated oxidative stress in envenomation pathology.
In early 1945, P-51C, D, and K variants also joined the Chinese Nationalist Air Force. These Mustangs were provided to the 3rd, 4th, and 5th Fighter Groups and used to attack Japanese targets in occupied areas of China. The P-51 became the most capable fighter in China, while the Imperial Japanese Army Air Force used the Nakajima Ki-84 Hayate against it. The P-51 was a relative latecomer to the Pacific theater, due largely to the need for the aircraft in Europe, plus the P-38 was already successful in the Pacific since its twin-engined design was considered a safety advantage for long, over-water flights. The first P-51s were deployed in the Far East later in 1944, operating in close-support and escort missions, as well as tactical photoreconnaissance. As the war in Europe wound down, the P-51 became more common in the Far East. With the capture of Iwo Jima, USAAF P-51 Mustang fighters of the VII Fighter Command were stationed on that island starting in March 1945, being initially tasked with escorting Boeing B-29 Superfortress missions against the Japanese homeland. Iwo Jima's extreme humidity and blowing volcanic dust made aircraft maintenance challenging. To achieve the range required on very-long range missions, the P-51's engine was operated for very long periods at minimum power settings, leading to lead fouling of the spark plugs which had to be replaced after each mission. P-51s would fly round trips of 1,500 miles, mostly flown over water with minimal navigation equipment, and these escort missions would take seven or eight hours.
Sources: en.wikipedia.org
In addition it yielded interesting data in terms of who are the main downloaders of the AIDA program, and has also provided technical (computer) information which aided the release of a freeware upgrade to the software. A second study audited 2,437 separate downloads of the AIDA program. The Internet-based survey methodology was confirmed to be robust and reliable. Over a 7.5-month period (from mid-July 2000 to early March 2001) 2,437 responses were received. During the corresponding period 4,100 actual downloads of the software were independently logged via the same route at the AIDA Website — giving a response rate to this audit of 59.4%. Responses were received from participants in 61 countries — although over half of these (n 5 1,533; 62.9%) originated from the United States and United Kingdom. Of these responses 1,361 (55.8%) were received from people with diabetes and 303 (12.4%) from relatives of patients, with fewer responses from doctors, diabetes educators, students, nurses, pharmacists, and other end users. This study has confirmed the feasibility of using the Internet to survey, at no real cost, a large number of medical software downloaders / users. In addition, it yielded up-to-date and interesting data about who are the main downloaders of the AIDA program. A third study surveyed downloaders of a more recent release of the program (AIDA v4.3a). Over a 1-year period (from March 2001 to February 2002) in total 3,864 responses were received.
=== EC 1.99.1 Hydroxylases (now covered by EC 1.14) === EC 1.99.1.1: deleted, Now EC 1.12.7.2, ferredoxin hydrogenase EC 1.99.1.2: deleted, Now EC 1.14.16.1, phenylalanine 4-monooxygenase EC 1.99.1.3: deleted, nicotinate 6-hydroxylase EC 1.99.1.4: deleted, tryptophan 5-hydroxylase EC 1.99.1.5: deleted, Now EC 1.14.13.9, kynurenine 3-monooxygenase EC 1.99.1.6: deleted, steroid 11α-hydroxylase EC 1.99.1.7: deleted, Now EC 1.14.15.4, steroid 11β-monooxygenase EC 1.99.1.8: deleted, steroid 6β-hydroxylase EC 1.99.1.9: deleted, Now EC 1.14.99.9, steroid 17α-monooxygenase EC 1.99.1.10: deleted, steroid 19-hydroxylase EC 1.99.1.11: deleted, Now EC 1.14.99.10, steroid 21-monooxygenase EC 1.99.1.12: deleted, alkoxyaryl hydroxylase EC 1.99.1.13: deleted, covered by EC 1.14.99.7 (squalene monooxygenase) and by EC 5.4.99.7 (lanosterol synthase) EC 1.99.1.14: deleted, Now EC 1.13.11.27, 4-hydroxyphenylpyruvate dioxygenase
== Reporting of yields == In their 2010 Synlett article, Martina Wernerova and organic chemist, Tomáš Hudlický, raised concerns about inaccurate reporting of yields, and offered solutions—including the proper characterization of compounds. After performing careful control experiments, Wernerova and Hudlický said that each physical manipulation (including extraction/washing, drying over desiccant, filtration, and column chromatography) results in a loss of yield of about 2%. Thus, isolated yields measured after standard aqueous workup and chromatographic purification should seldom exceed 94%. They called this phenomenon "yield inflation" and said that yield inflation had gradually crept upward in recent decades in chemistry literature. They attributed yield inflation to careless measurement of yield on reactions conducted on small scale, wishful thinking and a desire to report higher numbers for publication purposes.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.